0001193125-23-232026.txt : 20230911 0001193125-23-232026.hdr.sgml : 20230911 20230911081829 ACCESSION NUMBER: 0001193125-23-232026 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230911 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230911 DATE AS OF CHANGE: 20230911 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bausch Health Companies Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 231246745 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc. DATE OF NAME CHANGE: 20100928 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 8-K 1 d528926d8k.htm 8-K 8-K
0000885590 false 0000885590 2023-09-11 2023-09-11

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): September 11, 2023

 

 

Bausch Health Companies Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

British Columbia, Canada   001-14956   98-0448205

(State or Other Jurisdiction of

Incorporation or Organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

2150 St. Elzéar Blvd. West

Laval, Quebec

Canada H7L 4A8

(Address of Principal Executive Offices) (Zip Code)

514-744-6792

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Shares, No Par Value   BHC   New York Stock Exchange, Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01.

Other Events.

Acquisition Financing

On September 11, 2023, Bausch + Lomb Corporation (“Bausch + Lomb”), a subsidiary of Bausch Health Companies Inc. (the “Company”), announced that, in connection with the financing of its pending acquisition (the “Acquisition”) of XIIDRA® and certain other ophthalmology assets, Bausch + Lomb Escrow Corp. (the “Escrow Issuer”), a wholly owned subsidiary of Bausch + Lomb, launched an offering of $1.4 billion aggregate principal amount of new senior secured notes due 2028 (the “Notes”) and that Bausch + Lomb is seeking to enter into an incremental term loan facility (“Term Loan Facility”), which will be secured on a pari passu basis with Bausch + Lomb’s existing term loan facility and will either be in the form of an incremental amendment to Bausch + Lomb’s existing term loan facility or a separate credit agreement. Bausch + Lomb is expected to borrow $500 million of new term B loans (the “New Term B Loans”) under the Term Loan Facility upon the closing of the Acquisition.

The Notes will be offered in the United States to qualified institutional investors pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis, which is exempt from the prospectus requirements of such securities laws.

The net proceeds of the New Term B Loans and the offering of the Notes are expected to fund the Acquisition, to pay fees and expenses related to the Acquisition, the borrowings of the New Term B Loans and the offering of the Notes and for general corporate purposes, including the repayment of existing debt.

If the issuance of the Notes occurs prior to the closing of the Acquisition, the Notes will initially be issued by the Escrow Issuer and the net proceeds from the offering of the Notes will be deposited into a segregated escrow account. Upon closing of the Acquisition, Bausch + Lomb will assume the obligations of the Escrow Issuer under the Notes and the indenture that will govern the Notes and any other obligations of the Escrow Issuer and receive all of the assets of the Escrow Issuer, and the net proceeds will be released from the escrow account and applied as set forth above. However, if the issuance of the Notes occurs substantially concurrently with the closing of the Acquisition, Bausch + Lomb will be the issuer of the Notes.

Closing of the Term Loan Facility will be conditioned upon completion of the Acquisition and will occur concurrently with the closing of the Acquisition. Closing of the Notes offering will not be conditioned upon completion of the Acquisition, but if the Acquisition does not occur on or prior to September 30, 2024, the Escrow Issuer will be required to redeem the Notes at such time at a redemption price equal to the principal amount of the Notes plus any accrued and unpaid interest.

The foregoing transactions are subject to market and other conditions. There can be no assurance that Bausch + Lomb will be able to successfully complete the transactions, on the terms described above, or at all.

Also on September 11, 2023, the Company issued a press release relating to the Term Loan Facility and the offering of the Notes by Bausch + Lomb. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

This Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes will not be registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

 

Item 7.01.

Regulation FD Disclosure.

Leading up to the launch of the financing transactions described below, Bausch + Lomb, a subsidiary of Bausch Health Companies Inc., has continued to update its preliminary valuations of assets acquired and liabilities assumed in connection with its pending acquisition of XIIDRA® and certain other ophthalmology assets (the “Acquisition”), which has resulted in certain adjustments to the preliminary purchase price allocation included in the unaudited pro forma condensed combined financial information that was furnished on Form 8-K on September 6, 2023. The adjustments primarily include a reduction in Prepaid expenses and other current assets ($22 million) and a reduction in Other non-current liabilities ($12 million) offset by an increase in Goodwill ($10 million) in the Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30, 2023. These adjustments also resulted in corresponding reductions of expenses in the Unaudited Pro Forma Condensed Combined Statement of Operations for the six months ended June 30, 2023, the year ended December 31, 2022 and the six months ended June 30, 2022 of $20 million, $43 million and $20 million, respectively, primarily related to amortization of intangible assets. These adjustments did not impact revenue or Adjusted EBITDA. As of the date hereof, Bausch + Lomb has not completed the valuation analysis of identifiable assets acquired and liabilities assumed. Accordingly, the adjustments are preliminary and are subject to further adjustments as additional information becomes available and as additional analyses are performed subsequent to the close of the transaction.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K may contain forward-looking statements, including statements relating to Bausch + Lomb’s proposed financing and the closing of the Acquisition. Forward-looking statements may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health Companies Inc.’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, such risks and uncertainties include, but are not limited to, the following: uncertainties relating to the timing of the consummation of the Acquisition; the possibility that any or all of the conditions to the consummation of the Acquisition may not be satisfied or waived; the effect of the announcement or pendency of the Acquisition on Bausch + Lomb’s ability to maintain relationships with customers, suppliers, and other business partners; the impact of the Acquisition if consummated on Bausch + Lomb’s business, financial position and results of operations; risks relating to potential diversion of management attention away from Bausch + Lomb’s ongoing business operations; Bausch + Lomb’s ability to finance the transaction as anticipated and risks relating to increased levels of debt as a result of debt expected to be incurred to finance such transaction; and risks that Bausch + Lomb may not realize the expected benefits of that transaction on a timely basis or at all. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health Companies Inc. undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this Current Report on Form 8-K or to reflect actual outcomes, unless required by law.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

 

Exhibit
Number		    Description
99.1    Press release issued by the Company on September 11, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

BAUSCH HEALTH COMPANIES INC.
By:  

/s/ Seana Carson

Name:   Seana Carson
Title:   Executive Vice President, General Counsel

Date: September 11, 2023

 EX-99.1 2 d528926dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

Investor Contacts:

John O’Connor

ir@bauschhealth.com

(908) 541-2973

   

Media Contact:

Kevin Wiggins

coporate.communications@bauschhealth.com

(908) 541-3785

Mark Maico

ir@bauschhealth.com

(908) 541-2102

(877) 281-6642 (toll free)

   

Bausch Health’s Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

LAVAL, Quebec, September 11, 2023 – Bausch + Lomb Corporation (“Bausch + Lomb”) (NYSE/TSX: BLCO), a subsidiary of Bausch Health Companies Inc. (the “Company”) (NYSE/TSX: BHC), announced today that, in connection with the financing of its pending acquisition (the “Acquisition”) of XIIDRA® and certain other ophthalmology assets, Bausch + Lomb Escrow Corp. (the “Escrow Issuer”), a wholly owned subsidiary of Bausch + Lomb, launched an offering of $1.4 billion aggregate principal amount of new senior secured notes due 2028 (the “Notes”) and that Bausch + Lomb is seeking to enter into an incremental term loan facility (“Term Loan Facility”), which will be secured on a pari passu basis with Bausch + Lomb’s existing term loan facility and will either be in the form of an incremental amendment to Bausch + Lomb’s existing term loan facility or a separate credit agreement. Bausch + Lomb is expected to borrow $500 million of new term B loans (the “New Term B Loans”) under the Term Loan Facility upon the closing of the Acquisition.

The net proceeds of the New Term B Loans and the offering of the Notes are expected to fund the Acquisition, to pay fees and expenses related to the Acquisition, the borrowings of the New Term B Loans and the offering of the Notes and for general corporate purposes, including the repayment of existing debt.

Closing of the Term Loan Facility will be conditioned upon completion of the Acquisition and will occur concurrently with the closing of the Acquisition. Closing of the Notes offering will not be conditioned upon completion of the Acquisition, but if the Acquisition does not occur on or prior to September 30, 2024, the Escrow Issuer will be required to redeem the Notes at such time at a redemption price equal to the principal amount of the Notes plus accrued and unpaid interest.

The foregoing transactions are subject to market and other conditions. There can be no assurance that Bausch + Lomb will be able to successfully complete the transactions, on the terms described above, or at all.

The Notes will not be registered under the Securities Act of 1933, as amended (“Securities Act”), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Company has filed a Current Report on Form 8-K in connection with the above, a copy of which is also available on its SEDAR+ (www.sedarplus.ca) profile. This news release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

This news release may contain forward-looking statements about the future performance of Bausch Health, including statements relating to Bausch + Lomb’s proposed financing and the closing of the Acquisition, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “subject to” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health’s overall business, including those more fully described in Bausch Health’s most recent annual report on Form 10-K and detailed from time to time in Bausch Health’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, such risks and uncertainties include, but are not limited to, the following: uncertainties relating to the timing of the consummation of the Acquisition; the possibility that any or all of the conditions to the consummation of the Acquisition may not be satisfied or waived; the effect of the announcement or pendency of the Acquisition on Bausch + Lomb’s ability to maintain relationships with customers,

suppliers, and other business partners; the impact of the Acquisition if consummated on Bausch + Lomb’s business, financial position and results of operations; risks relating to potential diversion of management attention away from Bausch + Lomb’s ongoing business operations; Bausch + Lomb’s ability to finance the transaction as anticipated and risks relating to increased levels of debt as a result of debt expected to be incurred to finance such transaction, such as the Notes and the New Term B Loans; and risks that Bausch + Lomb may not realize the expected benefits of that transaction on a timely basis or at all. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

###

EX-101.SCH 3 bhc-20230911.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 bhc-20230911_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Country Entity Address, Country Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 5 bhc-20230911_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g528926g0909025819167.jpg GRAPHIC begin 644 g528926g0909025819167.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Sep. 11, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Sep. 11, 2023
Entity Registrant Name Bausch Health Companies Inc.
Entity Incorporation, State or Country Code A1
Entity File Number 001-14956
Entity Tax Identification Number 98-0448205
Entity Address, Address Line One 2150 St. Elzéar Blvd. West
Entity Address, City or Town Laval
Entity Address, State or Province QC
Entity Address, Country CA
Entity Address, Postal Zip Code H7L 4A8
City Area Code 514
Local Phone Number 744-6792
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, No Par Value
Trading Symbol BHC
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000885590
Amendment Flag false
XML 8 d528926d8k_htm.xml IDEA: XBRL DOCUMENT 0000885590 2023-09-11 2023-09-11 0000885590 false 8-K 2023-09-11 Bausch Health Companies Inc. A1 001-14956 98-0448205 2150 St. Elzéar Blvd. West Laval QC CA H7L 4A8 514 744-6792 false false false false Common Shares, No Par Value BHC NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d528926d8k.htm bhc-20230911.xsd bhc-20230911_lab.xml bhc-20230911_pre.xml d528926dex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d528926d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d528926d8k.htm" ] }, "labelLink": { "local": [ "bhc-20230911_lab.xml" ] }, "presentationLink": { "local": [ "bhc-20230911_pre.xml" ] }, "schema": { "local": [ "bhc-20230911.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bhc", "nsuri": "http://www.bauschhealth.com/20230911", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d528926d8k.htm", "contextRef": "duration_2023-09-11_to_2023-09-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d528926d8k.htm", "contextRef": "duration_2023-09-11_to_2023-09-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com//20230911/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-232026-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-232026-xbrl.zip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end